Literature DB >> 27441747

Stereotactic Body Radiation Therapy for Early-Stage Lung Cancer.

Genevieve Maquilan1, Robert Timmerman.   

Abstract

Stereotactic body radiation therapy (SBRT), also known as stereotactic ablative radiotherapy, is a technique of external beam radiation that delivers precisely targeted, ablative doses to extracranial sites. It has become an integral component of the management of early-stage non-small cell lung cancer (NSCLC). In this review, we discuss the technology and techniques used in treatment planning and delivery, the efficacy and toxicity of SBRT for medically inoperable early-stage NSCLC, and the preliminary investigations into the role of SBRT for operable early-stage NSCLC.

Entities:  

Mesh:

Year:  2016        PMID: 27441747     DOI: 10.1097/PPO.0000000000000204

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  4 in total

Review 1.  Charged-particle therapy in cancer: clinical uses and future perspectives.

Authors:  Marco Durante; Roberto Orecchia; Jay S Loeffler
Journal:  Nat Rev Clin Oncol       Date:  2017-03-14       Impact factor: 66.675

2.  Flattening filter-free technique in volumetric modulated arc therapy for lung stereotactic body radiotherapy: A clinical comparison with the flattening filter technique.

Authors:  Shuri Aoki; Hideomi Yamashita; Akihiro Haga; Kanabu Nawa; Toshikazu Imae; Wataru Takahashi; Osamu Abe; Keiichi Nakagawa
Journal:  Oncol Lett       Date:  2018-01-16       Impact factor: 2.967

3.  Planning benchmark study for SBRT of early stage NSCLC : Results of the DEGRO Working Group Stereotactic Radiotherapy.

Authors:  Christos Moustakis; Oliver Blanck; Fatemeh Ebrahimi Tazehmahalleh; Mark Ka Heng Chan; Iris Ernst; Thomas Krieger; Marciana-Nona Duma; Markus Oechsner; Ute Ganswindt; Christian Heinz; Horst Alheit; Hilbert Blank; Ursula Nestle; Rolf Wiehle; Christine Kornhuber; Christian Ostheimer; Cordula Petersen; Gerhard Pollul; Wolfgang Baus; Georg Altenstein; Eric Beckers; Katrin Jurianz; Florian Sterzing; Matthias Kretschmer; Heinrich Seegenschmiedt; Torsten Maass; Stefan Droege; Ulrich Wolf; Juergen Schoeffler; Uwe Haverkamp; Hans Theodor Eich; Matthias Guckenberger
Journal:  Strahlenther Onkol       Date:  2017-05-31       Impact factor: 3.621

4.  Improving interinstitutional and intertechnology consistency of pulmonary SBRT by dose prescription to the mean internal target volume dose.

Authors:  L Wilke; C Moustakis; O Blanck; D Albers; C Albrecht; Y Avcu; R Boucenna; K Buchauer; T Etzelstorfer; C Henkenberens; D Jeller; K Jurianz; C Kornhuber; M Kretschmer; S Lotze; K Meier; P Pemler; A Riegler; A Röser; D Schmidhalter; K H Spruijt; G Surber; V Vallet; R Wiehle; J Willner; P Winkler; A Wittig; M Guckenberger; S Tanadini-Lang
Journal:  Strahlenther Onkol       Date:  2021-07-01       Impact factor: 3.621

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.